Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Free Cash Flow (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Free Cash Flow data on record, last reported at -$30.5 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 16.93% year-over-year to -$30.5 million; the TTM value through Dec 2025 reached -$139.9 million, down 5.81%, while the annual FY2025 figure was -$139.9 million, 5.81% down from the prior year.
  • Free Cash Flow reached -$30.5 million in Q4 2025 per TNGX's latest filing, up from -$30.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$7.7 million in Q2 2021 and bottomed at -$41.7 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$28.0 million, with a median of -$30.7 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 24124900.0% in 2021, then increased 18.39% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$17.6 million in 2021, then crashed by 55.96% to -$27.4 million in 2022, then increased by 4.52% to -$26.2 million in 2023, then plummeted by 40.32% to -$36.8 million in 2024, then increased by 16.93% to -$30.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$30.5 million in Q4 2025, -$30.9 million in Q3 2025, and -$36.8 million in Q2 2025.